Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by nobody – 2019-04-05 08:37 (541 d 23:38 ago) – Posting: # 20124
Views: 2,134

» The fact that it is also a royal waste of money is of course only secondary.

Full-blown development mode. Accept it. Tell the sponsor you can't do the trial, if you are not qualified for PD-endpoint testing.

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
21,080 posts in 4,397 threads, 1,468 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Monday 08:15 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5